Drug
Tegoprubart clinical trials
Also written AT-1501.
- studies test it
- 10
- open now
- 4
- in phase 3
- 1
- first study started
- 2020
Keep track of what changes. Save the tegoprubart studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
9 studies that test it; most in 2022 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 9
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 2
Eledon Pharmaceuticals (6) · University of Chicago (2) · Anelixis Therapeutics, LLC (2)
Studies
Open first, then newest update. How each study uses tegoprubart is read from its arms, and is right about nine times in ten.
Testing it · 10
- Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney TransplantationNot yet recruitingPhase 3Eledon PharmaceuticalsNCT07835581Written as Tegoprubart
- Breakthrough - T1DM and Chronic Kidney DiseaseRecruitingPhase 1/2University of ChicagoNCT07592000Written as Tegoprubart
- Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant RecipientsEnrolling by invitationPhase 2Eledon PharmaceuticalsNCT06126380Written as AT-1501
- Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney TransplantRecruitingPhase 1/2Eledon PharmaceuticalsNCT05027906Written as AT-1501
- Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)Active, not recruitingPhase 1/2University of ChicagoNCT06305286Written as Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
- Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney TransplantationCompletedPhase 2Eledon PharmaceuticalsNCT05983770Written as AT-1501
- Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)TerminatedPhase 2Eledon PharmaceuticalsNCT05125068Written as AT-1501
- Multiple Doses of AT-1501-A201 in Adults With ALSCompletedPhase 2Anelixis Therapeutics, LLCNCT04322149Written as AT-1501
- Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1DWithdrawnPhase 1/2Eledon PharmaceuticalsNCT05480657Written as AT-1501 IV Infusion
- Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell TransplantationWithdrawnPhase 2Anelixis Therapeutics, LLCNCT04711226Written as AT-1501
Codes
What other systems call tegoprubart · ClinicalTrials.gg INT016469
- UNII (FDA) EK87C62XNHTEGOPRUBARTOne source FDA
- NCI Thesaurus C199118TegoprubartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | EK87C62XNH | TEGOPRUBART | One source FDA |
| NCI Thesaurus | C199118 | Tegoprubart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.